Harold Koendgen

2.2k total citations · 1 hit paper
38 papers, 1.4k citations indexed

About

Harold Koendgen is a scholar working on Pathology and Forensic Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Harold Koendgen has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Harold Koendgen's work include Multiple Sclerosis Research Studies (29 papers), Polyomavirus and related diseases (12 papers) and Acute Lymphoblastic Leukemia research (9 papers). Harold Koendgen is often cited by papers focused on Multiple Sclerosis Research Studies (29 papers), Polyomavirus and related diseases (12 papers) and Acute Lymphoblastic Leukemia research (9 papers). Harold Koendgen collaborates with scholars based in Switzerland, United States and Canada. Harold Koendgen's co-authors include Ludwig Kappos, Stephen L. Hauser, Jerry S. Wolinsky, Shibeshih Belachew, Marianna Manfrini, Douglas L. Arnold, Fabian Model, Pei‐Ran Ho, Ih Chang and Sandra Richman and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Harold Koendgen

37 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

2020 344 citations Ludwig Kappos, Jerry S. Wolinsky et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harold Koendgen Switzerland	15	1.1k	487	445	269	261	38	1.4k
Amy Pace United States	8	1.0k 0.9×	555 1.1×	300 0.7×	282 1.0×	252 1.0×	15	1.2k
Alexandros Tselis United States	21	729 0.6×	472 1.0×	319 0.7×	242 0.9×	151 0.6×	40	1.3k
M. Stojanovic Serbia	8	815 0.7×	361 0.7×	271 0.6×	249 0.9×	241 0.9×	18	1.0k
Joaquín Castilló Spain	22	1.4k 1.3×	644 1.3×	327 0.7×	510 1.9×	179 0.7×	48	1.7k
W. H. Stuart United States	7	1.1k 1.0×	439 0.9×	411 0.9×	333 1.2×	257 1.0×	8	1.5k
Bettina Stubinski Switzerland	14	1.2k 1.0×	512 1.1×	317 0.7×	489 1.8×	170 0.7×	18	1.3k
Marianna Manfrini Switzerland	7	737 0.6×	325 0.7×	221 0.5×	167 0.6×	205 0.8×	21	868
William H. Stuart United States	12	986 0.9×	343 0.7×	529 1.2×	213 0.8×	282 1.1×	19	1.3k
Marco Capobianco Italy	26	1.6k 1.4×	769 1.6×	591 1.3×	502 1.9×	547 2.1×	83	2.2k
Sandrine Wiertlewski France	19	740 0.7×	447 0.9×	140 0.3×	171 0.6×	428 1.6×	48	1.2k

Countries citing papers authored by Harold Koendgen

Since Specialization

Citations

This map shows the geographic impact of Harold Koendgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harold Koendgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harold Koendgen more than expected).

Fields of papers citing papers by Harold Koendgen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harold Koendgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harold Koendgen. The network helps show where Harold Koendgen may publish in the future.

Co-authorship network of co-authors of Harold Koendgen

This figure shows the co-authorship network connecting the top 25 collaborators of Harold Koendgen. A scholar is included among the top collaborators of Harold Koendgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harold Koendgen. Harold Koendgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benedict, Ralph H. B., Ludwig Kappos, Aaron Miller, et al.. (2025). Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials. Multiple Sclerosis and Related Disorders. 95. 106310–106310. 1 indexed citations

Hauser, Stephen L., Amit Bar‐Or, Martin S. Weber, et al.. (2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 10(2). 28 indexed citations

Kappos, Ludwig, Anthony Traboulsee, David K.B. Li, et al.. (2023). Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. Journal of Neurology. 271(2). 642–657. 10 indexed citations

Bar‐Or, Amit, Christopher Harp, Corrado Bernasconi, et al.. (2023). Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 93. 104662–104662. 46 indexed citations

Mammen, Andrew L., Anthony A. Amato, Mazen M. Dimachkie, et al.. (2023). Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. The Lancet Rheumatology. 5(2). e67–e76. 31 indexed citations

Arnold, Douglas L., Till Sprenger, Amit Bar‐Or, et al.. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Multiple Sclerosis Journal. 28(12). 1927–1936. 13 indexed citations

Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2021). Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 97(16). e1546–e1559. 115 indexed citations

Hauser, Stephen L., Nicolas Strauli, Christopher Harp, et al.. (2021). B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (4292). Neurology. 96(15_supplement). 3 indexed citations

Hughes, Richard A., Hans‐Martin Schneble, Erwan Muros‐Le Rouzic, et al.. (2020). COVID-19 in ocrelizumab-treated people with multiple sclerosis. Multiple Sclerosis and Related Disorders. 49. 102725–102725. 54 indexed citations

10.

Bar‐Or, Amit, Christopher Harp, Anne Cross, et al.. (2020). Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420). Neurology. 94(15_supplement). 1 indexed citations

11.

Horáková, Dana, Tomáš Uher, Jan Krásenský, et al.. (2020). Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Multiple Sclerosis and Related Disorders. 46. 102543–102543. 16 indexed citations

12.

Wolinsky, Jerry S., Douglas L. Arnold, Bruno Brochet, et al.. (2020). Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology. 19(12). 998–1009. 103 indexed citations

13.

Hauser, Stephen L., Ludwig Kappos, Douglas L. Arnold, et al.. (2020). Five years of ocrelizumab in relapsing multiple sclerosis. Neurology. 95(13). e1854–e1867. 106 indexed citations

14.

Kappos, Ludwig, Jerry S. Wolinsky, Gavin Giovannoni, et al.. (2020). Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology. 77(9). 1132–1132. 344 indexed citations breakdown →

15.

Bar‐Or, Amit, Robert Bermel, Martin S. Weber, et al.. (2020). Serum Ig Levels and Risk of Serious Infections by Baseline Ig Quartile in the Pivotal Phase III Trials and Open-Label Extensions of Ocrelizumab in Multiple Sclerosis (1173). Neurology. 94(15_supplement). 7 indexed citations

16.

Ho, Pei‐Ran, et al.. (2017). Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet Neurology. 16(11). 925–933. 209 indexed citations

17.

Giovannoni, Gavin, Gary Cutter, Maria Pia Sormani, et al.. (2017). Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders. 12. 70–78. 77 indexed citations

18.

Butzkueven, Helmut, Ludwig Kappos, María Trojano, et al.. (2016). Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069). Neurology. 86(16_supplement). 2 indexed citations

19.

Goodman, Andrew, Douglas L. Arnold, Ludwig Kappos, et al.. (2015). Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study (P7.260). Neurology. 84(14_supplement). 2 indexed citations

20.

Butzkueven, Helmut, Ludwig Kappos, María Trojano, et al.. (2015). Disease Course in Multiple Sclerosis (MS) Patients Switching from Fingolimod to Natalizumab (P3.284). Neurology. 84(14_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact